Lipid-based Non-viral Vector: Promising Approach for Gene Delivery.

IF 2.6 4区 医学 Q2 PHARMACOLOGY & PHARMACY Current pharmaceutical design Pub Date : 2024-09-24 DOI:10.2174/0113816128324084240828084904
Anupama Panday, Bhupendra Dixena, Nishant Jain, Akhlesh Kumar Jain
{"title":"Lipid-based Non-viral Vector: Promising Approach for Gene Delivery.","authors":"Anupama Panday, Bhupendra Dixena, Nishant Jain, Akhlesh Kumar Jain","doi":"10.2174/0113816128324084240828084904","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>The present review aims to discuss various strategies to overcome intracellular and extracellular barriers involved in gene delivery as well as the advantages, challenges, and mechanisms of gene delivery using non-viral vectors. Additionally, patents, clinical studies, and various formulation approaches related to lipid-based carrier systems are discussed.</p><p><strong>Methods: </strong>Data were searched and collected from Google Scholar, ScienceDirect, Pubmed, and Springer.</p><p><strong>Results: </strong>In this review, we have investigated the advantages of non-viral vectors over viral vectors. The advantage of using non-viral vectors are that they seek more attention in different fields. They play an important role in delivering the genetic materials. However, few nonviral vector-based carrier systems have been found in clinical settings. Challenges are developing more stable, site-specific gene delivery and conducting thorough safety assessments to minimize the undesired effects.</p><p><strong>Conclusion: </strong>In comparison to viral vectors, nonviral vector-based lipid nanocarriers have more advantages for gene delivery. Gene therapy research shows promise in addressing health concerns. Lipid-based nanocarriers can overcome intracellular and extracellular barriers, allowing efficient delivery of genetic materials. Non-viral vectors are more attractive due to their biocompatibility, ease of synthesis, and cost-effectiveness. They can deliver various nucleic acids and have improved gene delivery efficacy by avoiding degradation steps. Despite limited clinical use, many patents have been filed for mRNA vaccine delivery using non-viral vectors.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pharmaceutical design","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113816128324084240828084904","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: The present review aims to discuss various strategies to overcome intracellular and extracellular barriers involved in gene delivery as well as the advantages, challenges, and mechanisms of gene delivery using non-viral vectors. Additionally, patents, clinical studies, and various formulation approaches related to lipid-based carrier systems are discussed.

Methods: Data were searched and collected from Google Scholar, ScienceDirect, Pubmed, and Springer.

Results: In this review, we have investigated the advantages of non-viral vectors over viral vectors. The advantage of using non-viral vectors are that they seek more attention in different fields. They play an important role in delivering the genetic materials. However, few nonviral vector-based carrier systems have been found in clinical settings. Challenges are developing more stable, site-specific gene delivery and conducting thorough safety assessments to minimize the undesired effects.

Conclusion: In comparison to viral vectors, nonviral vector-based lipid nanocarriers have more advantages for gene delivery. Gene therapy research shows promise in addressing health concerns. Lipid-based nanocarriers can overcome intracellular and extracellular barriers, allowing efficient delivery of genetic materials. Non-viral vectors are more attractive due to their biocompatibility, ease of synthesis, and cost-effectiveness. They can deliver various nucleic acids and have improved gene delivery efficacy by avoiding degradation steps. Despite limited clinical use, many patents have been filed for mRNA vaccine delivery using non-viral vectors.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
脂质非病毒载体:有望实现基因传递的方法
目的:本综述旨在讨论克服基因递送过程中涉及的细胞内和细胞外障碍的各种策略,以及使用非病毒载体递送基因的优势、挑战和机制。此外,还讨论了与脂质载体系统相关的专利、临床研究和各种制剂方法:方法:从 Google Scholar、ScienceDirect、Pubmed 和 Springer 搜索和收集数据:在这篇综述中,我们研究了非病毒载体相对于病毒载体的优势。使用非病毒载体的优势在于它们在不同领域受到更多关注。它们在传递遗传物质方面发挥着重要作用。然而,在临床环境中发现的基于非病毒载体的载体系统还很少。目前面临的挑战是开发更稳定、针对特定部位的基因递送,并进行全面的安全评估,以尽量减少不良影响:结论:与病毒载体相比,基于非病毒载体的脂质纳米载体在基因递送方面更具优势。基因治疗研究在解决健康问题方面大有可为。脂质纳米载体可以克服细胞内和细胞外的障碍,从而实现基因材料的高效传递。非病毒载体因其生物相容性、易于合成和成本效益高而更具吸引力。它们可以递送各种核酸,并通过避免降解步骤提高基因递送效率。尽管临床应用有限,但使用非病毒载体递送 mRNA 疫苗已申请了许多专利。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.30
自引率
0.00%
发文量
302
审稿时长
2 months
期刊介绍: Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field. Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.
期刊最新文献
Screening of Natural Compounds as Inhibitor of Mpro SARS-CoV-2 Protein; A Molecular Dynamics Approach. The Rise of FLiRT Variants in the COVID-19 Pandemic: What We Know So Far. Therapeutic Potential of Neutralizing Monoclonal Antibodies (nMAbs) against SARS-CoV-2 Omicron Variant. Co-loading Radio-photosensitizer Agents on Polymer and Lipid-based Nanocarriers for Radio-photodynamic Therapy Purposes: Review. Screening of Optimal Phytoconstituents through in silico Docking, Toxicity, Pharmacokinetic, and Molecular Dynamics Approach for Fighting against Polycystic Ovarian Syndrome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1